ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ASLAN Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2024 was $0.00 Mil. ASLAN Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, ASLAN Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, ASLAN Pharmaceuticals's current FCF Yield % is -472.84%.

The historical rank and industry rank for ASLAN Pharmaceuticals's FCF Margin % or its related term are showing as below:

ASLN' s FCF Margin % Range Over the Past 10 Years
Min: -860.2 Med: -388.75 Max: -54.08
Current: -388.75

During the past 10 years, the highest FCF Margin % of ASLAN Pharmaceuticals was -54.08%. The lowest was -860.20%. And the median was -388.75%.

ASLN's FCF Margin % is ranked worse than
62.85% of 1047 companies
in the Biotechnology industry
Industry Median: -145.04 vs ASLN: -388.75

ASLAN Pharmaceuticals FCF Margin % Historical Data

The historical data trend for ASLAN Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASLAN Pharmaceuticals FCF Margin % Chart

ASLAN Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-860.20

-388.75

ASLAN Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ASLAN Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, ASLAN Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASLAN Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ASLAN Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ASLAN Pharmaceuticals's FCF Margin % falls into.

ASLAN Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ASLAN Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-46.65	/	12
	=	-388.75 %

ASLAN Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=	%

ASLAN Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of ASLAN Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190

Website

https://www.aslanpharma.com

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.